④Strandness DE Jr : Duplex Imaging for the Detection of Renal Artery Stenosis. Am J Kidney Dis 24 : 674―678,1994.
⑤Losito A, et al : Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition.Nephrol Dial Transplant 20 : 1604―1609, 2005.
⑥Hackam DG, et al : Angiotensin inhibition in renovascular disease : A population-based cohort study. Am Heart J156 : 549―555, 2008.
⑦Silva VS, et al : Pleiotropic effects of statins may improve outcomes in atherosclerotic renovascular disease. Am JHypertens 21 : 1163―1168, 2008.
⑧Cooper CJ, et al : Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 : 13―22, 2014.
⑨Herrmann SM, et al : Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions(CORAL). Nephrol Dial Transplant 30 : 366―375, 2015.
⑩Fujihara M, et al : Clinical outcome of renal artery stenting for hypertension and chronic kidney disease up to 12 months in the J-RAS Study―prospective, single-arm, multicenter clinical study. Circ J 79 : 351―359, 2015.
⑪)Kumagai H, et al : Captopril therapy following percutaneous transluminal angioplasty for bilateral renal arterystenosis. Arch Intern Med 149 : 1973―1976, 1989(. 現在の雑誌名:JAMA Intern Med)
⑫Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel sub- types and pharmacology in the kidney. Circ Res 2007; 100: 342–353.
⑬Abe M, Maruyama N, Suzuki H, et al. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding pro- tein in patients with chronic kidney disease. Heart Vessels 2013; 28: 480–489.
⑭Abe M, Okada K, Maruyama N, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268–273.
⑮Abe M, Maruyama N, Okada K, et al. Additive antioxida- tive effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albu- minuria. Hypertens Res 2011; 34: 935–941.
⑯エビデンスに基づく CKD 診療ガイドライン 2018
⑰Xie X, et al. Am J Kidney Dis 2016;67:728‒41.
⑱Nistor I, et al. Nephrol Dial Transplant 2017. doi:10.1093/ndt/gfx072.
⑲Brenner BM, et al. N Engl J Med 2001;345:861‒9.
⑳Kurokawa K, et al. Clin Exp Nephrol 2006;10:193‒200.
㉑Lewis EJ, et al. N Engl J Med 2001;345:851‒60.
㉒Agodoa LY, et al. JAMA 2001;285:2719‒28.
㉓ Kent DM, et al. J Am Soc Nephrol 2007;18:1959‒65.
㉔Hou FF, et al. N Engl J Med 2006;354:131‒40.
㉕Hsu TW, et al. JAMA Intern Med 2014;174:347‒54.
㉖Whelton PK, et al. Arch Intern Med 2005;165:1401‒9.
㉗Schmidt M, et al. BMJ 2017;356:j791.
㉘Clase CM, et al. Kidney Int 2017;91:683‒90.
㉙Ahmed AK, et al. Nephrol Dial Transplant 2010;25:3977‒82.
㉚ONTARGET Investigators, Yusuf S, et al. N Engl J Med 2008;358:1547‒59.
㉛Mann JF, et al. Lancet 2008;372:547‒53.
㉜ Fried LF, et al. N Engl J Med 2013;369:1892‒903.
㉝ Imai E, et al. Hypertens Res 2013;36:1051‒9.
㉞Elgendy IY, et al. Am J Hypertens 2015;28:576‒85. 26. Bavishi C, et al. Am J Cardiol 2016;118:1427‒36. 27. Hayashi K, et al. Hypertens Res 2010;33:1211‒20.
㊱Tanizaki Y, et al. Incidence and risk factors for subtypes of ce- rebral infarction in a general population: the Hisayama study. Stroke. 2000; 31: 2616-2622. PMID: 11062284
㊲Asayama K, et al.; Evidence for Cardiovascular Prevention From Obser vational Cohor ts in Japan (EPOCH-JAPAN) Research Group. Cardiovascular risk with and without antihypertensive drug treatment in the Japanese general population: participant- level meta-analysis. Hypertension. 2014; 63: 1189-1197. PMID: 24637661
㊳Ninomiya T, et al. Midlife and late-life blood pressure and demen- tia in Japanese elderly: the Hisayama study. Hypertension. 2011; 58: 22-28. PMID: 21555680
㊴Hozawa A, et al.; NIPPON DATA80 Research Group. High blood pressure in middle age is associated with a future decline in ac- tivities of daily living. NIPPON DATA80. J Hum Hypertens. 2009; 23: 546-552. PMID: 19092846
㊵Kadota A, et al.; NIPPON DATA Research Group. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care. 2007; 30: 1533-1538. PMID:
㊸Miura K, et al.; Japan Arteriosclerosis Longitudinal Study (JALS) Group. Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women: a meta- analysis of 16 cohort studies. Circulation. 2009; 119: 1892-1898. PMID: 19332464
㊹Hansen TW, et al.; IDACO Investigators. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens. 2007; 25: 1554-1564. PMID: 17620947
㊽Momiyama Y, et al. Prognostic value of plasma high-sensitivity C-
reactive protein levels in Japanese patients with stable coronary ar ter y disease: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. Atherosclerosis. 2009; 207: 272-276. PMID: 19439303
㊿Don-Wauchope AC, et al. Incremental predictive value of natri- uretic peptides for prognosis in the chronic stable heart failure population: a systematic review. Heart Fail Rev. 2014; 19: 521- 540. PMID: 25120174
①日本循環器学会.冠動脈病変の非侵襲的診断法に関するガイド ライン.Circ J. 2009; 73 Suppl III. http://www.j-circ.or.jp/guide- line/pdf/JCS2010_yamashina_h.pdf
③Niiranen TJ, et al. Comparison of agreement between clinic and home-measured blood pressure in the Finnish population: the Finn-HOME Study. J Hypertens. 2006; 24: 1549-1555. PMID: 16877957
⑦Ho PM, et al. Medication adherence: its importance in cardio- vascular outcomes. Circulation. 2009; 119: 3028-3035. PMID: 19528344
⑧Park C, et al. Cost-ef fectiveness Analyses of Antihyper tensive Medicines: A Systematic Review. Am J Prev Med. 2017; 53 Suppl: S131-S142. PMID: 29153114
⑨Moran AE, et al. Cost-ef fectiveness of hyper tension therapy ac- cording to 2014 guidelines. N Engl J Med. 2015; 372: 447-455. PMID: 25629742 (Erratum in N Engl J Med. 2015; 372: 1677.)
⑩Richman IB, et al. Cost-effectiveness of Intensive Blood Pressure Management. JAMA Cardiol. 2016; 1: 872-879. PMID: 27627731
⑪Bress AP, et al.; SPRINT Research Group. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2017; 377: 745-755. PMID: 28834469
⑫齊藤郁夫，他.医療経済の視点からみた日本の高血圧治療―ア ンジオテンシン II 受容体拮抗薬，カルシウム拮抗薬併用療法 の費用対効果―.Prog Med. 2009; 29: 376-385.
⑭Iwahori T, et al. Time to Consider Use of the Sodium-to-Potassi-um Ratio for Practical Sodium Reduction and Potassium Increase.Nutrients. 2017; 9: 700. PMID: 28678188
⑮Ndanuko RN, et al. Dietary Patterns and Blood Pressure in
Adults: A Systematic Review and Meta-Analysis of Randomized
⑰Yancy CW, et al.; American College of Cardiology Foundation. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: e147-e239. PMID: 23747642
⑱Gupta AK, et al. Compliance, safety, and effectiveness of fixed- dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010; 55: 399-407. PMID: 20026768
⑲Mallat SG, et al. Free versus Fixed Combination Antihyperten- sive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Anal
⑳日本循環器学会，日本心不全学会.急性・慢性心不全診療ガイ
ドライン(2017 年改訂版).2018. p.36-37.
㉑Messerli FH, et al. Are beta-blockers efficacious as first-line ther-
apy for hypertension in the elderly? A systematic review. JAMA.1998; 279: 1903-1907. PMID: 9634263
㉒Gress TW, et al. Hyper tension and antihyper tensive therapy as
risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000; 342: 905-912. PMID: 10738048
㉓Manrique C, et al. Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdomi- nal obesity. Hypertension. 2010; 55: 15-17. PMID: 19917873
㉔Pimenta E, et al. Ef fects of dietar y sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009; 54: 475-481. PMID: 19620517
㉕Hermida RC, et al. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of sub- jects with resistant hypertension. Am J Hypertens. 2010; 23: 432- 439. PMID: 20044740
㉖Frishman WH, et al. First-line therapy option with low-dose bi- soprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharma- col. 1995; 35: 182-188. PMID: 7751430
㉗Deary AJ, et al. Double-blind, placebo-controlled crossover com- parison of five classes of antihypertensive drugs. J Hypertens. 2002; 20: 771-777. PMID: 11910315
㉘Dear y AJ, et al. Influence of dr ugs and gender on the ar terial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond). 2002; 103: 493-499. PMID: 12401122
㉚Powers WJ, et al.; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Associa- tion. Stroke. 2018; 49: e46-e110. PMID: 29367334 (Erratum in Stroke. 2018; 49: e138, Stroke. 2018; 49: e233-e234.
㉜Hjalmarson A, et al.; MERIT-HF Study Group. Effects of con- trolled-release metoprolol on total mor tality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/ XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA. 2000; 283: 1295-1302. PMID: 10714728
㉝CIBIS-II Investigators and Committees. The Cardiac Insuffi- ciency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9-13. PMID: 10023943
㉞Packer M, et al.; Carvedilol Prospective Randomized Cumulative Sur vival Study Group. Ef fect of car vedilol on sur vival in severe chronic heart failure. N Engl J Med. 2001; 344: 1651-1658. PMID: 11386263
㉟Rahman M, et al.; ALLHAT Collaborative Research Group. Car- diovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006; 144: 172-180. PMID: 16461961
㊱Solomon SD, et al.; Prevention of Events With ACE Inhibition (PEACE) Investigators. Influence of albuminuria on cardiovascu- lar risk in patients with stable coronar y ar ter y disease. Circula- tion. 2007; 116: 2687-2693. PMID: 18025537
52: 381-386. PMID: 21371493
㊲日本動脈硬化学会.動脈硬化性疾患予防ガイドライン 2017 年版. 日本動脈硬化学会 ; 201
㊳Sever PS, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-1158. PMID: 12686036
㊵Power MC, et al. Life-course blood pressure in relation to brain volumes. Alzheimers Dement. 2016; 12: 890-899. PMID: 27139841 1318)Walker KA, et al. Defining the Relationship Between Hyperten- sion, Cognitive Decline, and Dementia: a Review. Curr Hypertens
Rep. 2017; 19: 24. PMID: 28299725
㊶Yaffe K, et al. Early adult to midlife cardiovascular risk factorsand cognitive function. Circulation. 2014; 129: 1560-1567. PMID:
